Endocrinology, Vol 136, 3632-3638, Copyright © 1995 by Endocrine Society

ARTICLES

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

H Dobnig and RT Turner
Department of Orthopedics, Mayo Clinic, Rochester, Minnesota 55905, USA.

Previous studies demonstrated that intermittent treatment with PTH increases osteoblast number and bone formation in growing and adult rats. The cellular mechanism for this increase in osteoblast number was investigated in 16-month-old female rats. Continuous [3H]thymidine infusion over a 1-week intermittent PTH [human PTH-(1-34)] treatment period was performed to determine the percentage of newly formed osteoblasts that originate from progenitor cells. To verify increases in bone formation, we performed histomorphometry and Northern blot analysis of selected bone matrix proteins. PTH treatment resulted in dramatic increases in fluorochrome-labeled perimeter (727%), osteoid perimeter (735%), osteoblast number (626%), and steady state mRNA levels of osteocalcin (946%) and type 1 collagen (> 1000%). Autoradiographic analysis of metaphyseal sections revealed no difference in the percentage of [3H]thymidine-labeled osteoblasts between PTH- and vehicle-treated groups (4.3 +/- 1.3% vs. 5.7 +/- 2.7%, respectively). Similar changes were observed in PTH-treated ovariectomized rats. As the PTH-induced increase in osteoblast number did not require proliferation of progenitor cells we carried out an additional experiment in adult ovariectomized rats to determine the onset of PTH action. Incorporation of [3H]proline in the distal femoral epiphysis of PTH-treated adult ovariectomized rats was increased within 24 h. We conclude that the rapid PTH-induced rise in bone formation did not require cell proliferation and was most likely due to activation of preexisting bone lining cells to osteoblasts.

This article has been cited by other articles:

				D. Gesty-Palmer, P. Flannery, L. Yuan, L. Corsino, R. Spurney, R. J. Lefkowitz, and L. M. Luttrell A {beta}-Arrestin-Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation Science Translational Medicine, October 7, 2009; 1(1): 1ra1 - 1ra1. [Abstract] [Full Text] [PDF]

				M. B. Lowry, S. Lotinun, A. A. Leontovich, M. Zhang, A. Maran, K. L. Shogren, B. K. Palama, K. Marley, U. T. Iwaniec, and R. T. Turner Osteitis Fibrosa Is Mediated by Platelet-Derived Growth Factor-A Via a Phosphoinositide 3-Kinase-Dependent Signaling Pathway in a Rat Model for Chronic Hyperparathyroidism Endocrinology, November 1, 2008; 149(11): 5735 - 5746. [Abstract] [Full Text] [PDF]

				B. Clarke Normal Bone Anatomy and Physiology Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S131 - S139. [Abstract] [Full Text] [PDF]

				T. Kawano, N. Troiano, D. J. Adams, J. Jun Wu, B.-h. Sun, and K. Insogna The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice Endocrinology, August 1, 2008; 149(8): 4009 - 4015. [Abstract] [Full Text] [PDF]

				J. Stroup, M. P. Kane, and A. M. Abu-Baker Teriparatide in the treatment of osteoporosis Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 532 - 539. [Abstract] [Full Text] [PDF]

				L. J. Raggatt, L. Qin, J. Tamasi, S. C. Jefcoat Jr., E. Shimizu, N. Selvamurugan, F. Y. Liew, L. Bevelock, J. H. M. Feyen, and N. C. Partridge Interleukin-18 Is Regulated by Parathyroid Hormone and Is Required for Its Bone Anabolic Actions J. Biol. Chem., March 14, 2008; 283(11): 6790 - 6798. [Abstract] [Full Text] [PDF]

				H. R. Johansson, R. Skripitz, and P. Aspenberg Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone J Bone Joint Surg Br, March 1, 2008; 90-B(3): 400 - 404. [Abstract] [Full Text] [PDF]

				S. Johnston, S. Andrews, V. Shen, F. Cosman, R. Lindsay, D. W. Dempster, and A. Iida-Klein The Effects of Combination of Alendronate and Human Parathyroid Hormone(1 34) on Bone Strength Are Synergistic in the Lumbar Vertebra and Additive in the Femur of C57BL/6J Mice Endocrinology, September 1, 2007; 148(9): 4466 - 4474. [Abstract] [Full Text] [PDF]

				Y.-H. Wang, Y. Liu, and D. W. Rowe Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E594 - E603. [Abstract] [Full Text] [PDF]

				D. J. Chung, C. H. M. Castro, M. Watkins, J. P. Stains, M. Y. Chung, V. L. Szejnfeld, K. Willecke, M. Theis, and R. Civitelli Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43 J. Cell Sci., October 15, 2006; 119(20): 4187 - 4198. [Abstract] [Full Text] [PDF]

				R. T. Turner, S. Lotinun, T. E. Hefferan, and E. Morey-Holton Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone J Appl Physiol, September 1, 2006; 101(3): 881 - 886. [Abstract] [Full Text] [PDF]

				S. Lotinun, J. D. Sibonga, and R. T. Turner Evidence that the Cells Responsible for Marrow Fibrosis in a Rat Model for Hyperparathyroidism Are Preosteoblasts Endocrinology, September 1, 2005; 146(9): 4074 - 4081. [Abstract] [Full Text] [PDF]

				S. C. Miller, B. L. Anderson, and B. M. Bowman Weaning Initiates a Rapid and Powerful Anabolic Phase in the Rat Maternal Skeleton Biol Reprod, July 1, 2005; 73(1): 156 - 162. [Abstract] [Full Text] [PDF]

				L. Qin, J. Tamasi, L. Raggatt, X. Li, J. H. M. Feyen, D. C. Lee, E. DiCicco-Bloom, and N. C. Partridge Amphiregulin Is a Novel Growth Factor Involved in Normal Bone Development and in the Cellular Response to Parathyroid Hormone Stimulation J. Biol. Chem., February 4, 2005; 280(5): 3974 - 3981. [Abstract] [Full Text] [PDF]

				F. Q. Pirih, A. Tang, I. C. Ozkurt, J. M. Nervina, and S. Tetradis Nuclear Orphan Receptor Nurr1 Directly Transactivates the Osteocalcin Gene in Osteoblasts J. Biol. Chem., December 17, 2004; 279(51): 53167 - 53174. [Abstract] [Full Text] [PDF]

				K. A Cappuzzo and J. C Delafuente Teriparatide for Severe Osteoporosis Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302. [Abstract] [Full Text] [PDF]

				T. Bellido, A. A. Ali, L. I. Plotkin, Q. Fu, I. Gubrij, P. K. Roberson, R. S. Weinstein, C. A. O'Brien, S. C. Manolagas, and R. L. Jilka Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts: A PUTATIVE EXPLANATION FOR WHY INTERMITTENT ADMINISTRATION IS NEEDED FOR BONE ANABOLISM J. Biol. Chem., December 12, 2003; 278(50): 50259 - 50272. [Abstract] [Full Text] [PDF]

				I. Ahmed, D. Gesty-Palmer, M. K. Drezner, and L. M. Luttrell Transactivation of the Epidermal Growth Factor Receptor Mediates Parathyroid Hormone and Prostaglandin F2{alpha}-Stimulated Mitogen-Activated Protein Kinase Activation in Cultured Transgenic Murine Osteoblasts Mol. Endocrinol., August 1, 2003; 17(8): 1607 - 1621. [Abstract] [Full Text] [PDF]

				L. Qin, P. Qiu, L. Wang, X. Li, J. T. Swarthout, P. Soteropoulos, P. Tolias, and N. C. Partridge Gene Expression Profiles and Transcription Factors Involved in Parathyroid Hormone Signaling in Osteoblasts Revealed by Microarray and Bioinformatics J. Biol. Chem., May 23, 2003; 278(22): 19723 - 19731. [Abstract] [Full Text] [PDF]

				Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats Endocrinology, May 1, 2003; 144(5): 2008 - 2015. [Abstract] [Full Text] [PDF]

				J. Li, R. L. Duncan, D. B. Burr, V. H. Gattone, and C. H. Turner Parathyroid Hormone Enhances Mechanically Induced Bone Formation, Possibly Involving L-Type Voltage-Sensitive Calcium Channels Endocrinology, April 1, 2003; 144(4): 1226 - 1233. [Abstract] [Full Text] [PDF]

				J.-J. Body, G. A. Gaich, W. H. Scheele, P. M. Kulkarni, P. D. Miller, A. Peretz, R. K. Dore, R. Correa-Rotter, A. Papaioannou, D. C. Cumming, et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4528 - 4535. [Abstract] [Full Text] [PDF]

				E. F. Gevers, N. Loveridge, and I. C. A. F. Robinson Bone Marrow Adipocytes: A Neglected Target Tissue for Growth Hormone Endocrinology, October 1, 2002; 143(10): 4065 - 4073. [Abstract] [Full Text] [PDF]

				M. Sato, J. Vahle, A. Schmidt, M. Westmore, S. Smith, E. Rowley, and L. Y. Ma Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH Endocrinology, September 1, 2002; 143(9): 3230 - 3242. [Abstract] [Full Text] [PDF]

				J. L. Vahle, M. Sato, G. G. Long, J. K. Young, P. C. Francis, J. A. Engelhardt, M. S. Westmore, Y. L. Ma, and J. B. Nold Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety Toxicol Pathol, April 1, 2002; 30(3): 312 - 321. [Abstract] [PDF]

				M. Machwate, S. Harada, C. T. Leu, G. Seedor, M. Labelle, M. Gallant, S. Hutchins, N. Lachance, N. Sawyer, D. Slipetz, et al. Prostaglandin Receptor EP4 Mediates the Bone Anabolic Effects of PGE2 Mol. Pharmacol., July 1, 2001; 60(1): 36 - 41. [Abstract] [Full Text]

				G. A. Rodan and T. J. Martin Therapeutic Approaches to Bone Diseases Science, September 1, 2000; 289(5484): 1508 - 1514. [Abstract] [Full Text]

				S. C. Manolagas Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis Endocr. Rev., April 1, 2000; 21(2): 115 - 137. [Abstract] [Full Text]

				R. T. Turner, G. L. Evans, J. M. Cavolina, B. Halloran, and E. Morey-Holton Programmed Administration of Parathyroid Hormone Increases Bone Formation and Reduces Bone Loss in Hindlimb-Unloaded Ovariectomized Rats Endocrinology, October 1, 1998; 139(10): 4086 - 4091. [Abstract] [Full Text] [PDF]

				H. A. Simmons, C. M. Pirie, D. D. Thompson, and H. Z. Ke Parathyroid Hormone (1-34) Increased Total Body Bone Mass in Aged Female Rats J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 341 - 344. [Abstract] [Full Text]

				G. L. Evans, E. Morey-Holton, and R. T. Turner Spaceflight has compartment- and gene-specific effects on mRNA levels for bone matrix proteins in rat femur J Appl Physiol, June 1, 1998; 84(6): 2132 - 2137. [Abstract] [Full Text] [PDF]

				J. W. M. Chow, S. Fox, C. J. Jagger, and T. J. Chambers Role for parathyroid hormone in mechanical responsiveness of rat bone Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E146 - E154. [Abstract] [Full Text] [PDF]

				H. Dobnig and R. T. Turner The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1-34) on Bone Histomorphometry and Serum Chemistry in Rats Endocrinology, November 1, 1997; 138(11): 4607 - 4612. [Abstract] [Full Text] [PDF]

				T. Onishi and K. Hruska Expression of p27Kip1 in Osteoblast-Like Cells during Differentiation with Parathyroid Hormone Endocrinology, May 1, 1997; 138(5): 1995 - 2004. [Abstract] [Full Text] [PDF]